当前位置: 首页 >> 检索结果
共有 3491 条符合本次的查询结果, 用时 2.6138368 秒

441. CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease.

作者: .;Christopher Ma.;Jurij Hanzel.;Remo Panaccione.;William J Sandborn.;Geert R D'Haens.;Vineet Ahuja.;Raja Atreya.;Charles N Bernstein.;Peter Bossuyt.;Brian Bressler.;Robert V Bryant.;Benjamin Cohen.;Jean-Frederic Colombel.;Silvio Danese.;Axel Dignass.;Marla C Dubinsky.;Phillip R Fleshner.;Richard B Gearry.;Stephen B Hanauer.;Ailsa Hart.;Paulo Gustavo Kotze.;Torsten Kucharzik.;Peter L Lakatos.;Rupert W Leong.;Fernando Magro.;Julian Panés.;Laurent Peyrin-Biroulet.;Zhihua Ran.;Miguel Regueiro.;Siddharth Singh.;Antonino Spinelli.;A Hillary Steinhart.;Simon P Travis.;C Janneke van der Woude.;Bruce Yacyshyn.;Takayuki Yamamoto.;Matthieu Allez.;Willem A Bemelman.;Amy L Lightner.;Edouard Louis.;David T Rubin.;Ellen J Scherl.;Corey A Siegel.;Mark S Silverberg.;Severine Vermeire.;Claire E Parker.;Stefanie C McFarlane.;Leonardo Guizzetti.;Michelle I Smith.;Niels Vande Casteele.;Brian G Feagan.;Vipul Jairath.
来源: Gastroenterology. 2022年163卷4期950-964页
End points to determine the efficacy and safety of medical therapies for Crohn's disease (CD) and ulcerative colitis (UC) are evolving. Given the heterogeneity in current outcome measures, harmonizing end points in a core outcome set for randomized controlled trials is a priority for drug development in inflammatory bowel disease.

442. Economic evaluations of radioembolization with Itrium-90 microspheres in hepatocellular carcinoma: a systematic review.

作者: J C Alonso.;I Casans.;F M González.;D Fuster.;A Rodríguez.;N Sánchez.;I Oyagüez.;R Burgos.;A O Williams.;N Espinoza.
来源: BMC Gastroenterol. 2022年22卷1期326页
Transarterial radioembolization (TARE) with yttrium-90 microspheres is a clinically effective therapy for hepatocellular carcinoma (HCC) treatment. This study aimed to perform a systematic review of the available economic evaluations of TARE for the treatment of HCC.

443. Giant cell tumor of soft tissue of the colon: a case report and review of the literature.

作者: Seung Woo Lee.;Jun Lee.;Seong Jung Kim.;Ran Hong.
来源: BMC Gastroenterol. 2022年22卷1期317页
A giant cell tumor (GCT) is a benign neoplasm characterized by mixture of mononuclear cells and multinucleated cells. A GCT of soft tissue (GCT-ST) is developed in various extraosseous sites, but GCT-ST of the gastrointestinal tract is very rare. GCT-ST usually has a benign course, but rare cases reported malignant potential of the tumor. Therefore, complete resection is required to prevent local recurrence or distant metastasis.

444. Diagnostic accuracy of DNA-based SDC2 methylation test in colorectal cancer screening: a meta-analysis.

作者: Lixing Wang.;Yu Liu.;Duohan Zhang.;Xiaoliang Xiong.;Tingting Hao.;Lili Zhong.;Yinlong Zhao.
来源: BMC Gastroenterol. 2022年22卷1期314页
A growing body of research suggests that methylated genes can be used as early diagnostic markers for cancer. Some studies on methylated Syndecan 2 (SDC2) have shown that it has a great diagnostic ability in colorectal cancer. This meta-analysis was aimed to estimate the diagnostic performance of methylated SDC2 as a potential novel biomarker to screen for the colorectal cancer.

445. Proactive Therapeutic Drug Monitoring Versus Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.

作者: Nghia H Nguyen.;Virginia Solitano.;Sudheer K Vuyyuru.;John K MacDonald.;Silje W Syversen.;Kristin Kaasen Jørgensen.;Eileen Crowley.;Christopher Ma.;Vipul Jairath.;Siddharth Singh.
来源: Gastroenterology. 2022年163卷4期937-949.e2页
Proactive therapeutic drug monitoring (TDM) has been proposed to improve outcomes in patients with inflammatory bowel disease (IBD) treated with tumor necrosis factor (TNF)α antagonists. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing proactive TDM with conventional management in patients with IBD.

446. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea.

作者: Anthony Lembo.;Shahnaz Sultan.;Lin Chang.;Joel J Heidelbaugh.;Walter Smalley.;G Nicholas Verne.
来源: Gastroenterology. 2022年163卷1期137-151页
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder associated with significant disease burden. This American Gastroenterological Association Guideline is intended to support practitioners in decisions about the use of medications for the pharmacological management of IBS with predominant diarrhea (IBS-D) and is an update of a prior technical review and guideline.

447. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation.

作者: Lin Chang.;Shahnaz Sultan.;Anthony Lembo.;G Nicholas Verne.;Walter Smalley.;Joel J Heidelbaugh.
来源: Gastroenterology. 2022年163卷1期118-136页
Irritable bowel syndrome (IBS) is a common disorder of gut-brain interaction associated with significant disease burden. This American Gastroenterological Association guideline is intended to support practitioners in decisions about the use of medications for the pharmacological management of IBS-C and is an update of a prior technical review and guideline.

448. Pancreatic involvement in Erdheim-Chester disease: a case report and review of the literature.

作者: Jia-Wen Dai.;Tian-Hua He.;Ming-Hui Duan.;Yue Li.;Xin-Xin Cao.
来源: BMC Gastroenterol. 2022年22卷1期302页
Erdheim-Chester disease (ECD) is a rare form of non-Langerhans cell histiocytosis characterized by infiltration of lipid-laden foamy macrophages within different tissues. Clinical manifestations of ECD are highly heterogeneous. Bone lesions are found in 80%-95% of patients, while extraosseous lesions usually involve the cardiovascular system, retroperitoneum, central nervous system (CNS), and skin. Pancreatic involvement in ECD has barely been reported.

449. Severe small intestinal bacterial overgrowth syndrome after jejunal feeding requiring surgical intervention: a case report and review of the literature.

作者: Majd B Aboona.;Tina W Wong.;Paul R Del Prado.;Keith Paley.;Ross F Goldberg.;Samuel Weimer.;Harikrishna Dave.;Dan Hobohm.;Adam Smith.
来源: BMC Gastroenterol. 2022年22卷1期300页
Small intestinal bacterial overgrowth (SIBO) is a condition of unknown prevalence characterized by an excessive amount of bacteria in the small bowel, typically resulting in vague gastrointestinal symptoms with bloating being most commonly reported. Here we describe a severe case of SIBO leading to small bowel necrosis requiring surgical intervention.

450. Altered Mycobiota Signatures and Enriched Pathogenic Aspergillus rambellii Are Associated With Colorectal Cancer Based on Multicohort Fecal Metagenomic Analyses.

作者: Yufeng Lin.;Harry Cheuk-Hay Lau.;Yali Liu.;Xing Kang.;Yiwei Wang.;Nick Lung-Ngai Ting.;Thomas Ngai-Yeung Kwong.;Jing Han.;Weixin Liu.;Changan Liu.;Junjun She.;Sunny Hei Wong.;Joseph Jao-Yiu Sung.;Jun Yu.
来源: Gastroenterology. 2022年163卷4期908-921页
The enteric mycobiota is a major component of the human gut microbiota, but its role in colorectal cancer (CRC) remains largely elusive. We conducted a meta-analysis to uncover the contribution of the fungal mycobiota to CRC.

451. Recent Advances in the Study of Extracellular Vesicles in Colorectal Cancer.

作者: Sarah E Glass.;Robert J Coffey.
来源: Gastroenterology. 2022年163卷5期1188-1197页
There has been significant progress in the study of extracellular vesicles (EVs) since the 2017 American Gastroenterological Association-sponsored Freston Conference "Extracellular Vesicles: Biology, Translation and Clinical Application in GI Disorders." The burgeoning interest in this field stems from the increasing recognition that EVs represent an understudied form of cell-to-cell communication and contain cargo replete with biomarkers and therapeutic targets. This short review will highlight recent advances in the field, with an emphasis on colorectal cancer. After a brief introduction to secreted particles, we will describe how our laboratory became interested in EVs, which led to refined methods of isolation and identification of 2 secreted nanoparticles. We will then summarize the cargo found in small EVs released from colorectal cancer cells and other cells in the tumor microenvironment, as well as those found in the circulation of patients with colorectal cancer. Finally, we will consider the continuing challenges and future opportunities in this rapidly evolving field.

452. Risk Factors for Abdominal Pain-Related Disorders of Gut-Brain Interaction in Adults and Children: A Systematic Review.

作者: Jasmine K Zia.;Adrienne Lenhart.;Pei-Lin Yang.;Margaret M Heitkemper.;Jason Baker.;Laurie Keefer.;Miguel Saps.;Callie Cuff.;Gregory Hungria.;Elizabeth J Videlock.;Lin Chang.
来源: Gastroenterology. 2022年163卷4期995-1023.e3页
Many studies have assessed risk factors of irritable bowel syndrome (IBS) and other abdominal pain-related disorders of gut-brain interaction (AP-DGBI); however, the role of these factors is unclear due to heterogeneous study designs. The aim of this systematic review was to extensively evaluate the literature and determine clinical risk and protective factors for the presence and persistence of AP-DGBI in children and adults.

453. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.

作者: Laurent Peyrin-Biroulet.;Perttu Arkkila.;Alessandro Armuzzi.;Silvio Danese.;Jordi Guardiola.;Jørgen Jahnsen.;Charles Lees.;Edouard Louis.;Milan Lukáš.;Walter Reinisch.;Xavier Roblin.;Minyoung Jang.;Han Geul Byun.;Dong-Hyeon Kim.;Sung Jeong Lee.;Raja Atreya.
来源: BMC Gastroenterol. 2022年22卷1期291页
There are limited comparative data for infliximab and vedolizumab in inflammatory bowel disease patients.

454. The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020.

作者: Eileen Morgan.;Isabelle Soerjomataram.;Harriet Rumgay.;Helen G Coleman.;Aaron P Thrift.;Jérôme Vignat.;Mathieu Laversanne.;Jacques Ferlay.;Melina Arnold.
来源: Gastroenterology. 2022年163卷3期649-658.e2页
The aim of this study was to provide an overview of the burden of esophageal cancer in 185 countries in 2020 and projections for the year 2040.

455. Risk of Cancer in Inflammatory Bowel Diseases: Umbrella Review and Reanalysis of Meta-analyses.

作者: Daniele Piovani.;Cesare Hassan.;Alessandro Repici.;Lorenza Rimassa.;Carmelo Carlo-Stella.;Georgios K Nikolopoulos.;Elio Riboli.;Stefanos Bonovas.
来源: Gastroenterology. 2022年163卷3期671-684页
To summarize the epidemiologic evidence and assess the validity of claimed associations of inflammatory bowel diseases (IBDs) with overall and site-specific cancer risk.

456. A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions.

作者: Evan S Dellon.;Paneez Khoury.;Amanda B Muir.;Chris A Liacouras.;Ekaterina Safroneeva.;Dan Atkins.;Margaret H Collins.;Nirmala Gonsalves.;Gary W Falk.;Jonathan M Spergel.;Ikuo Hirano.;Mirna Chehade.;Alain M Schoepfer.;Calies Menard-Katcher.;David A Katzka.;Peter A Bonis.;Albert J Bredenoord.;Bob Geng.;Elizabeth T Jensen.;Robert D Pesek.;Paul Feuerstadt.;Sandeep K Gupta.;Alfredo J Lucendo.;Robert M Genta.;Girish Hiremath.;Emily C McGowan.;Fouad J Moawad.;Kathryn A Peterson.;Marc E Rothenberg.;Alex Straumann.;Glenn T Furuta.;Seema S Aceves.
来源: Gastroenterology. 2022年163卷1期59-76页
Disease activity and severity of eosinophilic esophagitis (EoE) dictate therapeutic options and management, but the decision-making process for determining severity varies among practitioners. To reduce variability in practice patterns and help clinicians monitor the clinical course of the disease in an office setting, we aimed to create an international consensus severity scoring index for EoE.

457. Natural History of Alcohol-Associated Liver Disease: Understanding the Changing Landscape of Pathophysiology and Patient Care.

作者: Jasmohan S Bajaj.;Laura E Nagy.
来源: Gastroenterology. 2022年163卷4期840-851页
Alcohol use and consequent liver disease are major burdens that have worsened during the COVID-19 pandemic. There are several facets to the pathophysiology and clinical consequences of alcohol-use disorder (AUD) and progression to alcohol-associated liver disease (ALD) that require a concerted effort by clinicians and translational and basic science investigators. Several recent advances from bedside to bench and bench to bedside have been made in ALD. We focused this review on a case-based approach that provides a human context to these important advances across the spectrum of ALD.

458. Long-Term Impact of Helicobacter pylori Eradication Therapy on Gastric Cancer Incidence and Mortality in Healthy Infected Individuals: A Meta-Analysis Beyond 10 Years of Follow-Up.

作者: Alexander C Ford.;Yuhong Yuan.;Paul Moayyedi.
来源: Gastroenterology. 2022年163卷3期754-756.e1页

459. Hypomagnesemia in intestinal lymphangiectasia: a case report and review of the literature.

作者: Hao Feng.;Linfeng Zou.;Xiao Zhai.;Shengyu Zhang.;Jingnan Li.
来源: BMC Gastroenterol. 2022年22卷1期246页
Intestinal lymphangiectasia (IL) is a rare disease characterized by dilation of lymphatic vessels and leakage of lymphatic fluids into the intestinal lumen, causing depletion of lymphocytes, protein, lipids, fat-soluble vitamins, and electrolytes. Hypomagnesemia can occur in IL patients but is seldom discussed.

460. Signet-ring cell carcinoma of the duodenal bulb presenting with gastrointestinal hemorrhage: a case report and literature review.

作者: Nan Ye.;Xiaoxiao Bao.;Xiaokang Zhao.;Bin Wang.
来源: BMC Gastroenterol. 2022年22卷1期226页
Primary duodenal cancer (PDC) is rare, especially signet-ring cell carcinoma (SRCC) of the duodenal bulb, and it is commonly misdiagnosed as an ulceration. Here, we report a rare case of SRCC of the duodenal bulb presenting with gastrointestinal hemorrhage in an 82-year-old man.
共有 3491 条符合本次的查询结果, 用时 2.6138368 秒